Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes
February 25, 2019 16:01 ET
|
Immunomedics
Preparation for Resubmission of BLA for Sacituzumab Govitecan Continuing Phase 2 Data in mTNBC Published in New England Journal of Medicine Oral Presentation of Updated Phase 1/2 Results with...
Immunomedics Announces Publication of Triple-Negative Breast Cancer Data With Sacituzumab Govitecan in the New England Journal of Medicine
February 20, 2019 17:05 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics to Report Results for the Quarter and Six Months Ended December 31, 2018 and Host Conference Call and Webcast on February 25, 2019
February 19, 2019 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces Oral Presentation at the 2019 Genitourinary Cancers Symposium
February 11, 2019 17:15 ET
|
Immunomedics
MORRIS PLAINS, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application
January 17, 2019 20:12 ET
|
Immunomedics
MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics and Johnson Matthey Announce Strategic Manufacturing Partnership
December 26, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J. and DEVENS, Mass., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) and Johnson Matthey (LSE: JMAT), today announced the companies have expanded their...
Immunomedics To Present at the 37th Annual J.P. Morgan Healthcare Conference
December 19, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan
December 06, 2018 08:03 ET
|
Immunomedics
Updated Phase 2 Results in Metastatic Triple-Negative Breast Cancer to be Presented at The 2018 San Antonio Breast Cancer Symposium (SABCS) Continue to Show Meaningful Clinical Benefit Consistent with...
Immunomedics Announces Presentation at Upcoming Healthcare Conferences
November 08, 2018 08:00 ET
|
Immunomedics
MORRIS PLAINS, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
Immunomedics Announces First Quarter Fiscal 2019 Results and Provides Corporate Update
November 07, 2018 16:05 ET
|
Immunomedics
Strategic Manufacturing Partnership Entered into with Samsung BioLogics to Provide Anticipated Long-Term Supply of Sacituzumab Govitecan Commercial Launch Preparations Nearing Completion with 50...